News

On Tuesday, Amgen (NASDAQ: AMGN) stock hit its one-year high, on continued momentum from a far better-than-expected quarterly earnings report. The immediate catalyst was a post-earnings price target

Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are

The next three years have just become a bigger question mark for Pfizer (NYSE: PFE) than they were before. There are two competing factors taking shape, one internal to the drugmaker; the other is

As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all

A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give investors

Good news from the laboratory put some zip into AstraZeneca (NASDAQ: AZN) shares on Monday. The veteran pharmaceutical company's shares enjoyed a nearly 3% lift across the trading session as a

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib

UnitedHealth Group (NYSE: UNH) used to be a safe stock to hang on to. Its financials looked impressive, the business got bigger, it boosted its dividend, and it looked like a no-brainer stock to

A $5,000 investment may not seem like a large amount of money to invest in the stock market. But you can make the most of it by investing for the long haul, and picking modestly valued growth

The stock market caters to investors with almost any budget, especially with online brokers offering commission-free trading and fractional shares. Even with a modest sum, you can find quality

Veteran pharmaceutical company AstraZeneca (NASDAQ: AZN) delivered for investors on the second-to-last trading day of the week. Its shares rose by more than 3% across that trading session, thanks

The stock market is near all-time highs as Wall Street chugs through earnings season and eyes the end of the year just around the corner.

But not all stocks are hitting new heights. Some prominent

Income investors usually don't mind too much if a stock doesn't deliver tremendous gains, as long as it keeps the dividends flowing. They typically don't like it when a stock tumbles, though, as

Dividend yields are more than just an indication of how much income a stock will generate for investors. High yields are often a sign that a stock is trading hands at an attractive price point. When

One of the healthier stocks in the healthcare field Wednesday was Amgen (NASDAQ: AMGN). The biotech and pharmaceutical company published its third-quarter results the previous day after market

Eli Lilly (NYSE: LLY) manufactures a drug called tirzepatide, a GLP-1 dual receptor agonist, which it sells as Mounjaro for treating type 2 diabetes and Zepbound for weight loss. Tirzepatide became

Shares in Viking Therapeutics (NASDAQ: VKTX) rose by a whopping 44.9% in October, according to data provided by S&P Global Market Intelligence. The move occurred in three legs, and each one was

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly

The stock for pharmaceutical giant Merck (NYSE: MRK) was trading down more than 3% Monday morning. That's a big drop in just a few hours to start the week.

So, what's going on?

It might have to do

Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor Merck

Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook. Scooping up shares of great companies after they have experienced

Pfizer (NYSE: PFE) is one of the oldest and most respected pharmaceutical companies in the world. The stock is out of favor right now, trading down around 60% from its 2022 high-water mark. The

I can think of more than a few reasons why someone might want to invest in Pfizer (NYSE: PFE), the pharmaceutical giant. The best one, for me at the moment, is its huge dividend yield -- 7% as of

I don't like the term "growth stock" all that much. Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that textbook growth stocks